Skip to content
Austin Top 50
Author:
OncoC4
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
October 19, 2026
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
September 16, 2026
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
September 1, 2026